12:00 AM
 | 
Aug 08, 2016
 |  BC Week In Review  |  Company News  |  Deals

Eureka Therapeutics, Memorial Sloan Kettering, Juno Therapeutics deal

Memorial Sloan and Eureka granted Juno exclusive, worldwide rights to binding domains against three multiple myeloma (MM) targets. Juno will incorporate the targets into chimeric antigen receptor (CAR)...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >